Hepatitis b core protein modulators

Abstract

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:

1 . A compound 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof. 
     
     
         2 .- 11 . (canceled) 
     
     
         12 . A pharmaceutically acceptable composition comprising a compound of  claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
     
     
         13 . A method of treating a hepatitis B infection in a patient in need thereof, comprising administering an effective amount of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof. 
     
     
         14 . A method of treating a hepatitis B infection in a patient in need thereof, comprising administering a first compound selected from a compound of  claim 1 , or a pharmaceutically acceptable salt thereof, and optionally administering one or more additional compounds. 
     
     
         15 . A method of treating a hepatitis B infection in a patient in need thereof, comprising administering an amount of a compound of  claim 1 , or a pharmaceutically acceptable salt thereof, and administering another HBV capsid assembly promoter. 
     
     
         16 . A method of treating a hepatitis B infection in a patient in need thereof, comprising administering a first compound selected from  claim 1 , or a pharmaceutically acceptable salt thereof, and one or more other HBV agents each selected from the group consisting of HBV capsid assembly promoters, HBF viral polymerase interfering nucleosides, viral entry inhibitors, HBsAg secretion inhibitors, disruptors of nucleocapsid formation, cccDNA formation inhibitors, antiviral core protein mutant, HBc directed transbodies, RNAi targeting HBV RNA, immunostimulants, TLR-7/9 agonists, cyclophilin inhibitors, HBV vaccines, SMAC mimetics, epigenetic modulators, kinase inhibitors, and STING agonists.